Bayer Doubles OTC Presence In China With Dihon Acquisition
This article was originally published in PharmAsia News
Bayer AG acquired its second Chinese over-the-counter company to scale up amid the country’s OTC consolidation trend.
You may also be interested in...
Sanofi-Aventis has gained a leadership position in China's OTC cough/cold market with its $520.6 million acquisition of BMP Sunstone, the latest in the global pharma's parade of consumer health buys
The latest developments in a US Congressional draft bill to curb Chinese biotech operations in the US is separating contract manufacturing and research from gene sequencing service providers, which may give China's major contract players reasons to breathe easy.
Multiple factors were behind Merck & Co’s rise to ace AstraZeneca and others to become the leading pharma multinational in the world’s second-largest pharma market in 2023, including partnerships and competition and a strong position in the growing HPV vaccine sector.